SCHEMBL883669

SCHEMBL883669

Cc1ccc2oc3cc4oc5ccccc5c4cc3c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.60
MAPT P10636 8/20 0.53
KDM4E B2RXH2 5/20 0.53
HPGD P15428 5/20 0.53
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
AHR P35869 3/20 0.53
NPC1 O15118 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
RAB9A P51151 1/20 0.53
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.46
HSD17B10 Q99714 2/20 0.46
TP53 P04637 1/20 0.46
PGR P06401 1/20 0.44
BCAT1 P54687 2/20 0.44
MAOB P27338 2/20 0.44
TNKS O95271 1/20 0.44
PARP1 P09874 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15785771 0.94 MAPT (0.55) MAOAMAPTKDM4EHPGDALDH1A1
SCHEMBL808014 0.94 MAPT (0.59) MAOAMAPTKDM4EHPGDALDH1A1
SCHEMBL883673 0.92 MAOA (0.60) MAOAMAPTKDM4EHPGDALDH1A1
SCHEMBL12850723 0.87 MAPT (0.52) MAOAMAPTKDM4EHPGDALDH1A1
SCHEMBL16809358 0.86 AHR (0.55) MAOAMAPTKDM4EHPGDALDH1A1
SCHEMBL24398597 0.86 NPC1 (0.55) MAOAMAPTKDM4EHPGDALDH1A1
SCHEMBL30743074 0.86 AHR (0.59) MAOAMAPTKDM4EHPGDALDH1A1
SCHEMBL2628334 0.86 AHR (0.59) MAOAMAPTKDM4EHPGDALDH1A1
SCHEMBL1635601 0.85 AHR (0.68) MAOAMAPTKDM4EHPGDALDH1A1
SCHEMBL17899746 0.84 AHR (0.52) MAOAMAPTKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917913-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2024-02-27 US disclosed
US-11917913-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2024-02-27 US disclosed
US-20190280218-A1 SUBSTITUTED OXEPINES MERCK PATENT GMBH (DE) 2019-09-12 US disclosed
US-10374170-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2019-08-06 US disclosed
EP-2856528-B1 METAL COMPLEXES COMPRISING CONDENSED HETEROAROMATIC RINGS MERCK PATENT GMBH (DE) 2019-07-03 EP disclosed
EP-2673249-B1 SUBSTITUTED DIBENZONAPHTHACENE MERCK PATENT GMBH (DE) 2019-04-03 EP disclosed
EP-2651862-B1 SUBSTITUTED TETRAARYLBENZENES MERCK PATENT GMBH (DE) 2017-05-10 EP disclosed
US-9598637-B2 Phosphorus-containing metal complexes MERCK PATENT GMBH (DE) 2017-03-21 US disclosed
US-9598637-B2 Phosphorus-containing metal complexes MERCK PATENT GMBH (DE) 2017-03-21 US disclosed
EP-3121183-A1 METALS CONTAINING ORGANIC COMPLEXES Merck Patent GmbH (DE) 2017-01-25 EP disclosed
US-20130261708-A1 SUBSTITUTED TETRAARYLBENZENES MERCK PATENT GMBH (DE) 2013-10-03 US disclosed
US-20130253617-A1 PHOSPHORUS-CONTAINING METAL COMPLEXES MERCK PATENT GMBH (DE) 2013-09-26 US disclosed
US-20130253617-A1 PHOSPHORUS-CONTAINING METAL COMPLEXES MERCK PATENT GMBH (DE) 2013-09-26 US disclosed
WO-2013097920-A1 METAL COMPLEXES COMPRISING 1,2,3-TRIAZOLES MERCK PATENT GMBH (DE) 2013-07-04 WO disclosed
US-20130116755-A1 METAL COMPLEXES WITH ORGANIC LIGANDS AND USE THEREOF IN OLEDS MERCK PATENT GMBH (DE) 2013-05-09 US disclosed
US-20130116755-A1 METAL COMPLEXES WITH ORGANIC LIGANDS AND USE THEREOF IN OLEDS MERCK PATENT GMBH (DE) 2013-05-09 US disclosed
WO-2012107163-A1 SUBSTITUTED DIBENZONAPHTHACENE MERCK PATENT GMBH (DE) 2012-08-16 WO disclosed
WO-2012079678-A1 SUBSTITUTED TETRAARYLBENZENES MERCK PATENT GMBH (DE) 2012-06-21 WO disclosed
WO-2012038029-A1 PHOSPHORUS-CONTAINING METAL COMPLEXES MERCK PATENT GMBH (DE) 2012-03-29 WO disclosed
WO-2012007103-A1 METAL COMPLEXES WITH ORGANIC LIGANDS AND USE THEREOF IN OLEDS MERCK PATENT GMBH (DE) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11917913-B2 Substituted oxepines OXGR1, OXTR, OCIAD2 MAOA 161/4885MAPT 1547/4885KDM4E 710/4885
US-10374170-B2 Substituted oxepines OXGR1, OXTR, OCIAD2 MAOA 161/4885MAPT 1547/4885KDM4E 710/4885
US-20190280218-A1 SUBSTITUTED OXEPINES OXGR1, OXTR, OCIAD2 MAOA 161/4885MAPT 1547/4885KDM4E 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.